FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023626718> ?p ?o ?g. }

• W2023626718 endingPage "S25" @default.
• W2023626718 startingPage "S14" @default.
• W2023626718 abstract "Intervention with interferon-β (IFNβ) therapy counters early inflammatory damage to myelin and protects axons; such therapy might demonstrate greater efficacy earlier in the disease course compared with later when permanent damage has already occurred. Clinical trials conducted in patients with clinically isolated syndrome (CIS) show clinical benefits of early treatment of multiple sclerosis (MS), as evidenced by delayed conversion to clinically definite multiple sclerosis and reduced disability 3 years later; however, statistical significance is lost at 5 years. Moreover, in the CIS trials, patients who began treatment later in the course of MS did not benefit as much as those who began treatment earlier. In the treatment of relapsing-remitting multiple sclerosis (RRMS), immunomodulatory drug (IMD) therapy markedly reduced relapse rates and the burden of disease, as assessed by MRI. IFNβ therapy has demonstrated greater benefits in RRMS than in secondary progressive multiple sclerosis (SPMS). The SPMS trials consistently show reduction in relapse rates and accumulation of new MRI lesions, but have conflicting results for time to disability progression, which is the primary outcome measure in SPMS trials. Current evidence suggests that IFNβ therapy may be more effective in the early stages of SPMS, characterized by relapsing episodes and MRI evidence of greater brain lesion disease activity. Thus, intervention with IFNβ therapy is appropriate for all stages of MS except PPMS or non-relapsing SPMS. Intervention with glatiramer acetate is appropriate for RRMS. The balance of evidence indicates that early therapy is essential to delay the accumulation of irreversible neurologic damage and consequent disability." @default.
• W2023626718 created "2016-06-24" @default.
• W2023626718 creator A5025488742 @default.
• W2023626718 date "2010-12-27" @default.
• W2023626718 modified "2023-10-18" @default.
• W2023626718 title "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials" @default.
• W2023626718 cites W1576830483 @default.
• W2023626718 cites W1967507425 @default.
• W2023626718 cites W1973256647 @default.
• W2023626718 cites W1983999022 @default.
• W2023626718 cites W1997824576 @default.
• W2023626718 cites W2005506388 @default.
• W2023626718 cites W2015238396 @default.
• W2023626718 cites W2023385152 @default.
• W2023626718 cites W2034432056 @default.
• W2023626718 cites W2036769788 @default.
• W2023626718 cites W2043449974 @default.
• W2023626718 cites W2056736742 @default.
• W2023626718 cites W2061005334 @default.
• W2023626718 cites W2062660709 @default.
• W2023626718 cites W2069947868 @default.
• W2023626718 cites W2095666175 @default.
• W2023626718 cites W2097669496 @default.
• W2023626718 cites W2112246282 @default.
• W2023626718 cites W2115989506 @default.
• W2023626718 cites W2125422382 @default.
• W2023626718 cites W2132228594 @default.
• W2023626718 cites W2139367012 @default.
• W2023626718 cites W2141919552 @default.
• W2023626718 cites W2143134934 @default.
• W2023626718 cites W2146802292 @default.
• W2023626718 cites W2151041276 @default.
• W2023626718 cites W2152235057 @default.
• W2023626718 cites W2159963451 @default.
• W2023626718 cites W2163394083 @default.
• W2023626718 cites W2165547142 @default.
• W2023626718 cites W2166983650 @default.
• W2023626718 cites W2169098250 @default.
• W2023626718 cites W2171753008 @default.
• W2023626718 cites W2250122053 @default.
• W2023626718 cites W2313649737 @default.
• W2023626718 cites W2326826867 @default.
• W2023626718 cites W2332599890 @default.
• W2023626718 cites W2513768836 @default.
• W2023626718 cites W2574627421 @default.
• W2023626718 cites W2608367334 @default.
• W2023626718 cites W3148391369 @default.
• W2023626718 doi "https://doi.org/10.1212/wnl.0b013e3182050388" @default.
• W2023626718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21205678" @default.
• W2023626718 hasPublicationYear "2010" @default.
• W2023626718 type Work @default.
• W2023626718 sameAs 2023626718 @default.
• W2023626718 citedByCount "85" @default.
• W2023626718 countsByYear W20236267182012 @default.
• W2023626718 countsByYear W20236267182013 @default.
• W2023626718 countsByYear W20236267182014 @default.
• W2023626718 countsByYear W20236267182015 @default.
• W2023626718 countsByYear W20236267182016 @default.
• W2023626718 countsByYear W20236267182017 @default.
• W2023626718 countsByYear W20236267182018 @default.
• W2023626718 countsByYear W20236267182019 @default.
• W2023626718 countsByYear W20236267182020 @default.
• W2023626718 countsByYear W20236267182021 @default.
• W2023626718 countsByYear W20236267182022 @default.
• W2023626718 countsByYear W20236267182023 @default.
• W2023626718 crossrefType "journal-article" @default.
• W2023626718 hasAuthorship W2023626718A5025488742 @default.
• W2023626718 hasConcept C126322002 @default.
• W2023626718 hasConcept C141071460 @default.
• W2023626718 hasConcept C143998085 @default.
• W2023626718 hasConcept C168563851 @default.
• W2023626718 hasConcept C203014093 @default.
• W2023626718 hasConcept C2778577042 @default.
• W2023626718 hasConcept C2778609137 @default.
• W2023626718 hasConcept C2779134260 @default.
• W2023626718 hasConcept C2780640218 @default.
• W2023626718 hasConcept C2781028063 @default.
• W2023626718 hasConcept C2781156865 @default.
• W2023626718 hasConcept C529278444 @default.
• W2023626718 hasConcept C535046627 @default.
• W2023626718 hasConcept C71924100 @default.
• W2023626718 hasConceptScore W2023626718C126322002 @default.
• W2023626718 hasConceptScore W2023626718C141071460 @default.
• W2023626718 hasConceptScore W2023626718C143998085 @default.
• W2023626718 hasConceptScore W2023626718C168563851 @default.
• W2023626718 hasConceptScore W2023626718C203014093 @default.
• W2023626718 hasConceptScore W2023626718C2778577042 @default.
• W2023626718 hasConceptScore W2023626718C2778609137 @default.
• W2023626718 hasConceptScore W2023626718C2779134260 @default.
• W2023626718 hasConceptScore W2023626718C2780640218 @default.
• W2023626718 hasConceptScore W2023626718C2781028063 @default.
• W2023626718 hasConceptScore W2023626718C2781156865 @default.
• W2023626718 hasConceptScore W2023626718C529278444 @default.
• W2023626718 hasConceptScore W2023626718C535046627 @default.
• W2023626718 hasConceptScore W2023626718C71924100 @default.
• W2023626718 hasIssue "1, Supplement 1" @default.
• W2023626718 hasLocation W20236267181 @default.
• W2023626718 hasLocation W20236267182 @default.

• next